People who receive the BioNTech/Pfizer COVID-19 vaccine produce ten times more antibodies than those vaccinated with the Chinese drug Sinovac, the South China Morning Post reported, citing a study.

According to the study, the level of antibodies produced during Sinovac vaccination was the same and even lower than that which is recorded in people who have had COVID-19 naturally. Therefore, it is recommended to introduce a booster dose of the vaccine for the most vulnerable groups of the population, including the elderly and people with weak immunity.

Scientists note that even an average level of the body's defense is better than its absence. Lead researcher Benjamin Cowling said the study's results are in line with the vaccine manufacturers' claims of effectiveness, with Pfizer at 95% and Sinovac at 50.7%.

The study also found that the average antibody level of 267 in the subgroup of 12 people who received the Pfizer vaccine was ten times higher than the same number of people in the Sinovac subgroup who had 27.